PTPN11 and lung carcinoma: ERK phosphorylation levels are concomitant with SHP2 phosphorylation after long‐term application of TKIs as well as RAS/MAPK inhibitors.[33] Compared with traditional SHP2 inhibitors, embelin inhibited the negative feedback occurring in RAS‐mutant lung cancer cells, which was manifested by the long‐term inhibition of SHP2 and ERK phosphorylation, whereas the levels of ERK and SHP2 phosphorylation were restored to some degree by the addition of SHP099 (Figure 7A,B).